 Home > Biochemistry News > Biotechnology News > Intellia collaborates on the development of CRISPR gene editing therapy to treat blinding eye disease

Intellia collaborates on the development of CRISPR gene editing therapy to treat blinding eye disease

 Last Update: 2021-10-19
 Source: Internet
 Author: User

Tags

3 1 simplified

glenhaven therapeutics

Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

On October 13, 2021, Intellia Therapeutics and SparingVision jointly announced that the two parties have reached a strategic cooperation to jointly develop new gene editing therapies based on CRISPR/Cas9 technology to treat ophthalmic diseases

Professor Emmanuelle Charpentier and Professor Jennifer Doudna, pioneers of CRISPR gene editing research, won the Nobel Prize in Chemistry last year

SparingVision is committed to the development of gene therapy for the treatment of retinitis pigmentosa

As part of this collaboration, SparingVision will obtain the exclusive rights to use Intellia's proprietary CRISPR/Cas9 in vivo genome editing technology for up to 3 ocular targets to treat diseases with significant unmet medical needs

Reference materials:

[1] Intellia Therapeutics and SparingVision Announce Strategic Collaboration to Develop Novel Ocular Therapies Using CRISPR/Cas9 Technology.

(The original text has been deleted)

This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

Related Products

L-Ascorbate-2-Monophosphate Feed Grade

CAS No.: 109620-90-8

Feed Grade

Potassium Sorbate from reliable manufacturer

CAS No.: 590-00-1

Food Grade

Doxycycline Hydrochloride

CAS No.: 10592-13-9

Pharmaceutical Grade

Hot Tags

united states jobs(223)

jobs united states(236)

1 year treasury(277)

1 year subscription(296)

single use technology(195)

announcements today(81)

ups united states(221)

united states logo(227)

80 20 company(94)

healthy food name(42)

Hot Articles

The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.